HCA Healthcare (HCA) traded lower today (down about 3% to around $464.53) as investors focused on 2026 earnings risk tied to reimbursement and payer-mix uncertainty, including Marketplace-related headwinds that management has flagged as a meaningful revenue drag in 2026. At the same time, the decline fit a pattern of profit-taking after the stock’s strong climb into a 52-week high in early February 2026, leaving shares more sensitive to incremental negative macro/policy signals heading into the next earnings report in late April.

HCA’s latest formal outlook for 2026 calls for revenue of $76.5 billion to $80.0 billion and diluted EPS of $29.10 to $31.50, but the debate has shifted to whether operating leverage and execution can offset government and commercial reimbursement crosscurrents. Recent market commentary has emphasized a potentially sizable 2026 hit tied to Health Insurance Marketplace dynamics and related volume changes, reinforcing caution around payer mix and margins even if demand remains steady.

Near-term attention is turning to HCA’s next earnings report (widely expected around April 24, 2026) and any updates on volumes, labor and supply costs, and payer mix trends. Investors will also look for commentary on the durability of 2026 guidance, as well as any incremental detail on how policy shifts could flow through to admissions, pricing, and margin in the back half of 2026.